Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer

Nicole Sänger, Eugen Ruckhäberle, B. Györffy, Knut Engels, Tomas Heinrich, Tanja Fehm, Anna Graf, Uwe Holtrich, Sven Becker, Thomas Karn

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Acid ceramidase (ASAH1) a key enzyme of sphingolipid metabolism converting pro-apoptotic ceramide to sphingosine has been shown to be overexpressed in various cancers. We previously demonstrated higher expression of ASAH1 in ER positive compared to ER negative breast cancer. In the current study we performed subtype specific analyses of ASAH1 gene expression in invasive and non invasive breast cancer. We show that expression of ASAH1 is mainly associated with luminal A - like cancers which are known to have the best prognosis of all breast cancer subtypes. Moreover tumors with high ASAH1 expression among the other subtypes are also characterized by an improved prognosis. The good prognosis of tumors with high ASAH1 is independent of the type of adjuvant treatment in breast cancer and is also detected in non small cell lung cancer patients. Moreover, even in pre-invasive DCIS of the breast ASAH1 is associated with a luminal phenotype and a reduced frequency of recurrences. Thus, high ASAH1 expression is generally associated with an improved prognosis in invasive breast cancer independent of adjuvant treatment and could also be valuable as prognostic factor for pre-invasive DCIS.

Original languageEnglish
Pages (from-to)58-67
Number of pages10
JournalMolecular Oncology
Volume9
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Acid Ceramidase
Carcinoma, Intraductal, Noninfiltrating
Breast Neoplasms
Neoplasms
Sphingolipids
Sphingosine
Ceramides
Non-Small Cell Lung Carcinoma
Breast
Phenotype
Gene Expression
Recurrence
Enzymes
Therapeutics

Keywords

  • Acid ceramidase
  • Breast cancer
  • Ceramide
  • Ductal carcinoma in situ
  • Prognosis
  • Sphingolipids

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer. / Sänger, Nicole; Ruckhäberle, Eugen; Györffy, B.; Engels, Knut; Heinrich, Tomas; Fehm, Tanja; Graf, Anna; Holtrich, Uwe; Becker, Sven; Karn, Thomas.

In: Molecular Oncology, Vol. 9, No. 1, 01.01.2015, p. 58-67.

Research output: Contribution to journalArticle

Sänger, N, Ruckhäberle, E, Györffy, B, Engels, K, Heinrich, T, Fehm, T, Graf, A, Holtrich, U, Becker, S & Karn, T 2015, 'Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer', Molecular Oncology, vol. 9, no. 1, pp. 58-67. https://doi.org/10.1016/j.molonc.2014.07.016
Sänger, Nicole ; Ruckhäberle, Eugen ; Györffy, B. ; Engels, Knut ; Heinrich, Tomas ; Fehm, Tanja ; Graf, Anna ; Holtrich, Uwe ; Becker, Sven ; Karn, Thomas. / Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer. In: Molecular Oncology. 2015 ; Vol. 9, No. 1. pp. 58-67.
@article{35b122a9838b4a01adbef46204766568,
title = "Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer",
abstract = "Acid ceramidase (ASAH1) a key enzyme of sphingolipid metabolism converting pro-apoptotic ceramide to sphingosine has been shown to be overexpressed in various cancers. We previously demonstrated higher expression of ASAH1 in ER positive compared to ER negative breast cancer. In the current study we performed subtype specific analyses of ASAH1 gene expression in invasive and non invasive breast cancer. We show that expression of ASAH1 is mainly associated with luminal A - like cancers which are known to have the best prognosis of all breast cancer subtypes. Moreover tumors with high ASAH1 expression among the other subtypes are also characterized by an improved prognosis. The good prognosis of tumors with high ASAH1 is independent of the type of adjuvant treatment in breast cancer and is also detected in non small cell lung cancer patients. Moreover, even in pre-invasive DCIS of the breast ASAH1 is associated with a luminal phenotype and a reduced frequency of recurrences. Thus, high ASAH1 expression is generally associated with an improved prognosis in invasive breast cancer independent of adjuvant treatment and could also be valuable as prognostic factor for pre-invasive DCIS.",
keywords = "Acid ceramidase, Breast cancer, Ceramide, Ductal carcinoma in situ, Prognosis, Sphingolipids",
author = "Nicole S{\"a}nger and Eugen Ruckh{\"a}berle and B. Gy{\"o}rffy and Knut Engels and Tomas Heinrich and Tanja Fehm and Anna Graf and Uwe Holtrich and Sven Becker and Thomas Karn",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.molonc.2014.07.016",
language = "English",
volume = "9",
pages = "58--67",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer

AU - Sänger, Nicole

AU - Ruckhäberle, Eugen

AU - Györffy, B.

AU - Engels, Knut

AU - Heinrich, Tomas

AU - Fehm, Tanja

AU - Graf, Anna

AU - Holtrich, Uwe

AU - Becker, Sven

AU - Karn, Thomas

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Acid ceramidase (ASAH1) a key enzyme of sphingolipid metabolism converting pro-apoptotic ceramide to sphingosine has been shown to be overexpressed in various cancers. We previously demonstrated higher expression of ASAH1 in ER positive compared to ER negative breast cancer. In the current study we performed subtype specific analyses of ASAH1 gene expression in invasive and non invasive breast cancer. We show that expression of ASAH1 is mainly associated with luminal A - like cancers which are known to have the best prognosis of all breast cancer subtypes. Moreover tumors with high ASAH1 expression among the other subtypes are also characterized by an improved prognosis. The good prognosis of tumors with high ASAH1 is independent of the type of adjuvant treatment in breast cancer and is also detected in non small cell lung cancer patients. Moreover, even in pre-invasive DCIS of the breast ASAH1 is associated with a luminal phenotype and a reduced frequency of recurrences. Thus, high ASAH1 expression is generally associated with an improved prognosis in invasive breast cancer independent of adjuvant treatment and could also be valuable as prognostic factor for pre-invasive DCIS.

AB - Acid ceramidase (ASAH1) a key enzyme of sphingolipid metabolism converting pro-apoptotic ceramide to sphingosine has been shown to be overexpressed in various cancers. We previously demonstrated higher expression of ASAH1 in ER positive compared to ER negative breast cancer. In the current study we performed subtype specific analyses of ASAH1 gene expression in invasive and non invasive breast cancer. We show that expression of ASAH1 is mainly associated with luminal A - like cancers which are known to have the best prognosis of all breast cancer subtypes. Moreover tumors with high ASAH1 expression among the other subtypes are also characterized by an improved prognosis. The good prognosis of tumors with high ASAH1 is independent of the type of adjuvant treatment in breast cancer and is also detected in non small cell lung cancer patients. Moreover, even in pre-invasive DCIS of the breast ASAH1 is associated with a luminal phenotype and a reduced frequency of recurrences. Thus, high ASAH1 expression is generally associated with an improved prognosis in invasive breast cancer independent of adjuvant treatment and could also be valuable as prognostic factor for pre-invasive DCIS.

KW - Acid ceramidase

KW - Breast cancer

KW - Ceramide

KW - Ductal carcinoma in situ

KW - Prognosis

KW - Sphingolipids

UR - http://www.scopus.com/inward/record.url?scp=84920567046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920567046&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2014.07.016

DO - 10.1016/j.molonc.2014.07.016

M3 - Article

VL - 9

SP - 58

EP - 67

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 1

ER -